Table 5. Association with protein expression of EID3 in IHC and the clinicopathological features of NF-pNET patients.
| Characteristic | EID3 high (n = 7) | EID3 low (n = 24) | p-value | |
|---|---|---|---|---|
| n | n | |||
| Gender | Male | 2 | 11 | 0.6672 |
| Female | 5 | 13 | ||
| Age | <54 | 4 | 12 | >0.9999 |
| ≥54 | 3 | 12 | ||
| Tumor size | <17 mm | 3 | 9 | >0.9999 |
| ≥17 mm | 4 | 15 | ||
| Grade | G1 | 1 | 10 | 0.3717 |
| G2 | 6 | 14 | ||
| T | T1, T2 | 3 | 11 | >0.9999 |
| T3, T4 | 4 | 13 | ||
| N | N0 | 4 | 16 | 0.6757 |
| N1 | 3 | 8 | ||
| M | M0 | 6 | 20 | >0.9999 |
| M1 | 1 | 4 | ||
| Stage | I, II | 3 | 15 | 0.413 |
| III, IV | 4 | 9 |
NF-pNET: non-functional pancreatic neuroendocrine tumors, Abs: antibodies